Expert Systems Celebrates Completion Of Single Dose Studies And Start Of Multiple Human Dosing For Lomonitinib, A Selective Pan-flt3/irak4 Inhibitor, Achieved In Just 3 Years

Expert Systems and Eilean Therapeutics have successfully completed a Phase 1 clinical trial for lomonitinib, a potential treatment for FLT3-mutated AML. The drug has shown a strong safety profile and was developed in just 3 years with the help of Expert Systems’ AI platform. Lomonitinib is a highly potent and selective inhibitor of FLT3 and IRAK4, addressing two common mechanisms of resistance to FLT3 inhibitors.